4.7 Article

A Spatio-Temporal Analysis of Matrix Protein and Nucleocapsid Trafficking during Vesicular Stomatitis Virus Uncoating

期刊

PLOS PATHOGENS
卷 6, 期 7, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.ppat.1000994

关键词

-

资金

  1. NIH [AI22470]
  2. NCRR [S10 RR13725]

向作者/读者索取更多资源

To study VSV entry and the fate of incoming matrix (M) protein during virus uncoating we used recombinant viruses encoding M proteins with a C-terminal tetracysteine tag that could be fluorescently labeled using biarsenical (Lumio) compounds. We found that uncoating occurs early in the endocytic pathway and is inhibited by expression of dominant-negative (DN) Rab5, but is not inhibited by DN-Rab7 or DN-Rab11. Uncoating, as defined by the separation of nucleocapsids from M protein, occurred between 15 and 20 minutes post-entry and did not require microtubules or an intact actin cytoskeleton. Unexpectedly, the bulk of M protein remained associated with endosomal membranes after uncoating and was eventually trafficked to recycling endosomes. Another small, but significant fraction of M distributed to nuclear pore complexes, which was also not dependent on microtubules or polymerized actin. Quantification of fluorescence from high-resolution confocal micrographs indicated that after membrane fusion, M protein diffuses across the endosomal membrane with a concomitant increase in fluorescence from the Lumio label which occurred soon after the release of RNPs into the cytoplasm. These data support a new model for VSV uncoating in which RNPs are released from M which remains bound to the endosomal membrane rather than the dissociation of M protein from RNPs after release of the complex into the cytoplasm following membrane fusion.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Multidisciplinary Sciences

Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever

Sergio E. Rodriguez, Robert W. Cross, Karla A. Fenton, Dennis A. Bente, Chad E. Mire, Thomas W. Geisbert

SCIENTIFIC REPORTS (2019)

Correction Multidisciplinary Sciences

Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants (vol 7, 9730, 2017)

Krista Versteeg, Andrea R. Menicucci, Courtney Woolsey, Chad E. Mire, Joan B. Geisbert, Robert W. Cross, Krystle N. Agans, Daniel Jeske, Ilhem Messaoudi, Thomas W. Geisbert

SCIENTIFIC REPORTS (2019)

Article Medicine, Research & Experimental

Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity

Kathleen M. McAndrews, Dara P. Dowlatshahi, Jianli Dai, Lisa M. Becker, Janine Hensel, Laura M. Snowden, Jennifer M. Leveille, Michael R. Brunner, Kylie W. Holden, Nikolas S. Hopkins, Alexandria M. Harris, Jerusha Kumpati, Michael A. Whitt, J. Jack Lee, Luis L. Ostrosky-Zeichner, Ramesha Papanna, Valerie S. LeBleu, James P. Allison, Raghu Kalluri

JCI INSIGHT (2020)

Article Cardiac & Cardiovascular Systems

Generation of SARS-CoV-2 Spike Pseudotyped Virus for Viral Entry and Neutralization Assays: A 1-Week Protocol

Jose Manuel Condor Capcha, Guerline Lambert, Derek M. Dykxhoorn, Alessandro G. Salerno, Joshua M. Hare, Michael A. Whitt, Savita Pahwa, Dushyantha T. Jayaweera, Lina A. Shehadeh

Summary: Studying the viral entry mechanisms of SARS-CoV-2 is crucial for developing therapeutic approaches for COVID-19, and a simple and effective method has been developed for producing pseudoviruses carrying the SARS-CoV-2 spike, suitable for studying viral infection in various cell lines.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)

Article Biochemistry & Molecular Biology

Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins

Ha V. Dang, Robert W. Cross, Viktoriya Borisevich, Zachary A. Bornholdt, Brandyn R. West, Yee-Peng Chan, Chad E. Mire, Sofia Cheliout Da Silva, Antony S. Dimitrov, Lianying Yan, Moushimi Amaya, Chanakha K. Navaratnarajah, Larry Zeitlin, Thomas W. Geisbert, Christopher C. Broder, David Veesler

Summary: The research describes two cross-reactive F-specific antibodies, 1F5 and 12B2, that neutralize NiV and HeV through inhibition of membrane fusion by recognizing distinct prefusion-specific epitopes. The structural and functional characterization of these antibodies demonstrate the therapeutic potential of using antibody cocktails to protect against henipavirus infection. This study defines a roadmap for developing effective countermeasures against highly pathogenic viruses.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2021)

Article Cell Biology

Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection

Taylor B. Engdahl, Natalia A. Kuzmina, Adam J. Ronk, Chad E. Mire, Matthew A. Hyde, Nurgun Kose, Matthew D. Josleyn, Rachel E. Sutton, Apoorva Mehta, Rachael M. Wolters, Nicole M. Lloyd, Francisca R. Valdivieso, Thomas G. Ksiazek, Jay W. Hooper, Alexander Bukreyev, James E. Crowe

Summary: The study found that the human response to New World hantaviruses infection has a convergent and potently neutralizing antibody reaction, with some monoclonal antibodies capable of broadly recognizing and cross-neutralizing both New and Old World hantaviruses. These antibodies hold therapeutic potential against HCPS.

CELL REPORTS (2021)

Article Microbiology

Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals

Debora Stelitano, Stuart P. Weisberg, Monica P. Goldklang, Yun Zhu, Francesca T. Bovier, Gavreel F. Kalantarov, Giuseppe Greco, Didier Decimo, Gianluigi Franci, Michele Cennamo, Giuseppe Portella, Massimiliano Galdiero, Cyrille Mathieu, Branka Horvat, Ilya N. Trakht, Anne Moscona, Michael A. Whitt, Matteo Porotto

Summary: This study introduces a new platform strategy for assessing virus-neutralizing activity and a cell-based immunofluorescent assay to accurately measure the neutralization potential of antibodies, providing useful tools for evaluating antiviral immunity acquired through natural infection or vaccination.

MSPHERE (2021)

Article Immunology

A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19

Delphine C. Malherbe, Drishya Kurup, Christoph Wirblich, Adam J. Ronk, Chad Mire, Natalia Kuzmina, Noor Shaik, Sivakumar Periasamy, Matthew A. Hyde, Julie M. Williams, Pei-Yong Shi, Matthias J. Schnell, Alexander Bukreyev

Summary: The study developed a SARS-CoV-2 ConVac vaccine which, through animal experiments, showed that a single dose of the vaccine could rapidly control viral replication after disease challenge, protecting animals from weight loss and lung virus replication, with some inflammation still detected.

NPJ VACCINES (2021)

Article Microbiology

An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization

Nicholas Wohlgemuth, Kendall Whitt, Sean Cherry, Ericka Kirkpatrick Roubidoux, Chun-Yang Lin, Kim J. Allison, Ashleigh Gowen, Pamela Freiden, E. Kaitlynn Allen, Aditya H. Gaur, Jeremie H. Estepp, Li Tang, Tomi Mori, Diego R. Hijano, Hana Hakim, Maureen A. McGargill, Florian Krammer, Michael A. Whitt, Joshua Wolf, Paul G. Thomas, Stacey Schultz-Cherry

Summary: This study evaluated the correlation of six serological assays with authentic virus neutralization for SARS-CoV-2. The results showed that luciferase- and SEAP-expressing pseudotyped virus neutralizations were the most accurate in predicting authentic virus neutralization, followed by GFP-expressing pseudotyped virus neutralization, and then ELISAs. This research outlines the advantages and disadvantages of different assays, providing insights into the optimal surrogate assay for authentic virus neutralization and enhancing the accuracy of assessing protective immunity against SARS-CoV-2 post infection and vaccination.

MICROBIOLOGY SPECTRUM (2021)

Article Immunology

A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2

Philipp A. Ilinykh, Sivakumar Periasamy, Kai Huang, Natalia A. Kuzmina, Palaniappan Ramanathan, Michelle N. Meyer, Chad E. Mire, Ivan V. Kuzmin, Preeti Bharaj, Jessica R. Endsley, Maria Chikina, Stuart C. Sealfon, Steven G. Widen, Mark A. Endsley, Alexander Bukreyev

Summary: Respiratory tract vaccination induces immune responses at the portal of SARS-CoV-2 entry, including neutralizing antibodies and memory T cell responses, providing advantages against COVID-19.

NPJ VACCINES (2022)

Article Biochemistry & Molecular Biology

Enveloped viruses pseudotyped with mammalian myogenic cell fusogens target skeletal muscle for gene delivery

Sajedah M. Hindi, Michael J. Petrany, Elena Greenfeld, Leah C. Focke, Alyssa A. W. Cramer, Michael A. Whitt, Ramzi J. Khairallah, Christopher W. Ward, Jeffrey S. Chamberlain, Benjamin Podbilewicz, Vikram Prasad, Douglas P. Millay

Summary: The muscle-specific fusogens Myomaker and Myo-merger can replace viral fusogens to mediate membrane fusion and deliver therapeutic genes to skeletal muscle. By engineering these muscle fusogens onto enveloped viruses, targeted transduction of skeletal muscle is achieved, providing a potential treatment for Duchenne muscular dystrophy.
Article Entomology

The increasing threat of Rift Valley fever virus globalization: strategic guidance for protection and preparation

Seth Gibson, Leela E. Noronha, Heidi Tubbs, Lee W. Cohnstaedt, William C. Wilson, Chad Mire, Dana Mitzel, Assaf Anyamba, Melinda Rostal, Kenneth J. Linthicum, Ary Faraji

Summary: Rift Valley fever virus (RVFV) is a vector-borne zoonotic disease that poses a threat to global agriculture and public health. It can be transmitted by mosquitoes and direct contact with infected tissues. With changing climate and environmental factors, the virus may be introduced to new areas. However, understanding the virus's transmission patterns and evolutionary factors can help reduce the risk of outbreaks.

JOURNAL OF MEDICAL ENTOMOLOGY (2023)

Article Multidisciplinary Sciences

A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection

Adam J. Ronk, Nicole M. Lloyd, Min Zhang, Caroline Atyeo, Hailee R. Perrett, Chad E. Mire, Kathryn M. Hastie, Rogier W. Sanders, Philip J. M. Brouwer, Erica Olmann Saphire, Andrew B. Ward, Thomas G. Ksiazek, Juan Carlos Alvarez Moreno, Harshwardhan M. Thaker, Galit Alter, Sunny Himansu, Andrea Carfi, Alexander Bukreyev

Summary: The study presents an mRNA-based Lassa virus vaccine that provides protection against lethal infection in a guinea pig model without the need for neutralizing antibodies. Vaccination induced strong binding antibody responses and demonstrated the potential of mRNA vaccines as a platform against Lassa virus.

NATURE COMMUNICATIONS (2023)

Article Immunology

Fatal Multisystem Inflammatory Syndrome in Adult after SARS-CoV-2 Natural Infection and COVID-19 Vaccination

Heather N. Grome, Michael Threlkeld, Steve Threlkeld, Charles Newman, Roosecelis Brasil Martines, Sarah Reagan-Steiner, Michael A. Whitt, Maria Gomes-Solecki, Nisha Nair, Mary-Margaret Fill, Timothy F. Jones, William Schaffner, John Dunn

Summary: This case describes a fatal instance of multisystem inflammatory syndrome in an adult occurring 22 days after receiving the second dose of an mRNA coronavirus vaccine. Both serologic and clinical findings suggested the infection of SARS-CoV-2 happened before the vaccination. The immunopathology of this syndrome, regardless of vaccination status, is still poorly understood.

EMERGING INFECTIOUS DISEASES (2021)

Article Medicine, Research & Experimental

Attenuated activation of pulmonary immune cells in mRNA-1273-vaccinated hamsters after SARS-CoV-2 infection

Michelle Meyer, Yuan Wang, Darin Edwards, Gregory R. Smith, Aliza B. Rubenstein, Palaniappan Ramanathan, Chad E. Mire, Colette Pietzsch, Xi Chen, Yongchao Ge, Wan Sze Cheng, Carole Henry, Angela Woods, LingZhi Ma, Guillaume B. E. Stewart-Jones, Kevin W. Bock, Mahnaz Minai, Bianca M. Nagata, Sivakumar Periasamy, Pei-Yong Shi, Barney S. Graham, Ian N. Moore, Irene Ramos, Olga G. Troyanskaya, Elena Zaslavsky, Andrea Carfi, Stuart C. Sealfon, Alexander Bukreyev

Summary: The study demonstrates that the mRNA-1273 vaccine is effective in hamsters against SARS-CoV-2, inducing robust neutralizing antibodies and reducing disease severity. It also shows the impact of the vaccine on immune cell infiltration, lymphocyte proportion, and antiviral responses conducive to lung health.

JOURNAL OF CLINICAL INVESTIGATION (2021)

暂无数据